Prenuvo Shares Early Results from Whole-Body MRI Trial, Highlighting Preventive Potential
Prenuvo has released preliminary findings from its prospective clinical trial evaluating the benefits of elective whole-body MRI in asymptomatic individuals. These early results suggest that such imaging may help identify a wide range of serious and treatable conditions before symptoms arise, bolstering the case for proactive screening.
The study, presented at the 2024 ISMRM (International Society for Magnetic Resonance in Medicine) meeting, includes data from over 3,000 patients who underwent non-contrast whole-body MRI scans between April 2022 and April 2023. The scans assessed 49 organs and body systems in just under an hour, using AI-assisted technology. Importantly, none of the participants were referred for imaging due to existing symptoms or known medical issues.
Key results show that 93% of participants had at least one previously undiagnosed finding. Of these, 29% were classified as requiring follow-up or treatment. Conditions ranged from aneurysms and cysts to more serious concerns like early-stage cancers and vascular abnormalities.
“This is the first prospective trial we are aware of that investigates the impact of whole-body MRI in asymptomatic patients,” said Dr. Raj Attariwala, a radiologist and co-founder of Prenuvo. “We believe this can significantly change how we think about and deliver preventive health care.”
The research also revealed that 2% of participants had potentially life-threatening findings, including aneurysms and early cancers that were discovered long before clinical symptoms might have appeared. Prenuvo emphasized that early identification of such conditions could lead to timely interventions and better outcomes.
While whole-body MRI has been a topic of growing interest in preventive medicine, critics have questioned its cost-effectiveness and risk of false positives. However, the Prenuvo study seeks to provide real-world evidence supporting its clinical value.
“These results reinforce the role of MRI as a powerful diagnostic tool—not just for investigating symptoms, but for proactively managing health,” said Attariwala. “This kind of screening can empower people with critical health information before it’s too late.”
The company plans to continue following patients in this trial to assess long-term health outcomes, treatment decisions, and cost implications. More comprehensive data will be shared in future phases of the study.